Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
Crossref DOI link: https://doi.org/10.1007/s10928-017-9550-0
Published Online: 2017-11-04
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Aoki, Yasunori http://orcid.org/0000-0002-5881-2023
Röshammar, Daniel
Hamrén, Bengt
Hooker, Andrew C.
Funding for this research was provided by:
AstraZeneca R&D Mölndal
License valid from 2017-11-04